CN103768056B - Amoxicillin and clavulanate potassium dispersible tablet - Google Patents
Amoxicillin and clavulanate potassium dispersible tablet Download PDFInfo
- Publication number
- CN103768056B CN103768056B CN201410028419.8A CN201410028419A CN103768056B CN 103768056 B CN103768056 B CN 103768056B CN 201410028419 A CN201410028419 A CN 201410028419A CN 103768056 B CN103768056 B CN 103768056B
- Authority
- CN
- China
- Prior art keywords
- prescription
- dispersible tablet
- amoxicillin
- clavulanate potassium
- disintegration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses an amoxicillin and clavulanate potassium dispersible tablet applied to the field of a preparation of the amoxicillin and clavulanate potassium dispersible tablet. The dispersible tablet is prepared from the following components: amoxicillin trihydrate, clavulanate potassium, microcrystalline cellulose, a disintegrant, diatomite, a sweetener and an aromatic, wherein the disintegrant is selected from one of croscarmellose sodium, carboxymethyl starch sodium and polyvinylpolypyrrolidone; the disintegrant is preferably selected from croscarmellose sodium; the sweetener is selected from one of aspartame and sucralose; the aromatic is selected from one of a blueberry flavor and a lemon essence; the sweetener is preferably selected from sucralose; the aromatic is preferably selected from the blueberry flavor; the weight ratio of amoxicillin trihydrate to clavulanate potassium in the dispersible tablet is 4:1 based on amoxicillin and clavulanate; the dispersible tablet is prepared from powder by a direct compression method. The amoxicillin and clavulanate potassium dispersible tablet is rapid to disintegrate, still can be rapidly disintegrated at low water temperature, and is good in stability, good in mouthfeel, simple in prescription, good in mobility of mixed powder in the prescription, and not sticking in the tabletting process.
Description
Technical field
The present invention relates to a kind of amoxicillin and clavulanate potassium dispersible tablet in amoxicillin and clavulanate potassium compound preparation field.
Background technology
Amoxicillin and clavulanate potassium dispersible tablet is made up of Utimox and clavulanate potassium.The compound preparation of the amoxicillin and clavulanate potassium compound preparation beta-lactam inhibitor that to be Britain release in the eighties in last century than Qie Mu company and semisynthetic penicillin composition.The molecular formula of Utimox is C
16h
19n
3o
5s3H
2o, molecular weight is 419.46, and the molecular formula of amoxicillin is C
16h
19n
3o
5s, molecular weight 365.4042.The molecular formula of clavulanate potassium is C
8h
8kNO
5, molecular weight is 237.25, and the molecular formula of clavulanic acid is C
8h
9nO
5, molecular weight is 199.16.The ratio of amoxicillin and clavulanate potassium has 2:1,4:1,5:1,7:1,10:1,14:1 and 16:1 etc., and its ratio is in amoxicillin and clavulanic acid.Amoxicillin and clavulanate potassium dispersible tablet is applicable to the various infection such as responsive microbial peritonitis, skin and soft tissue infection, otitis media, osteomyelitis, cystitis, pelvic inflammatory disease.The antimicrobial spectrum of this product is identical with amoxicillin, and expands to some extent.To product enzyme staphylococcus aureus, staphylococcus epidermidis, coagulase negative staphylococcus and the equal tool good action of enterococcus, also there is better antibacterial activity to the intestinal liver Rhizobiaceae bacterium, hemophilus influenza, moraxelle catarrhalis, bacteroides fragilis etc. that some produces beta-lactamase.This product produces the enterobacteriaceae lactobacteriaceae of Chromosome-encoded I type enzyme and Rhodopseudomonas without effect to methicillin-resistant Staphylococcus and Enterobacter etc.The Chinese market sales volume of amoxicillin and clavulanate potassium compound preparation in 2002 reaches 11.82 hundred million yuans.
Amoxicillin and clavulanate potassium (4:1) dispersible tablet is current clinical conventional a kind of amoxicillin and clavulanate potassium dispersible tablet specification.But it is long to there is disintegration, prescription mixed powder poor fluidity, easily sticking, prescription is more complicated, the problem such as taste bad will, poor stability.Therefore, the new recipe developing a kind of amoxicillin and clavulanate potassium dispersible tablet is new problem urgently to be resolved hurrily always.
Summary of the invention
The object of the present invention is to provide a kind of amoxicillin and clavulanate potassium dispersible tablet, this product disintegrate is quick, still can fater disintegration under lower water temperature, and good stability, mouthfeel is good, and the prescription of dispersible tablet is simple, mixed powder good fluidity, tableting processes not sticking.
The object of the present invention is achieved like this: a kind of amoxicillin and clavulanate potassium dispersible tablet, described dispersible tablet is made up of the component of following weight percents: Utimox 18.95%-25.26%, clavulanate potassium 4.92%-6.55%, microcrystalline Cellulose 62.35%-68.79%, disintegrating agent 2.2%-2.75%, kieselguhr 1.29%-6.13%, sweeting agent 0.11%-0.50%, aromatic 0.22%-0.28%; Described disintegrating agent is selected from the one in cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, polyvinylpolypyrrolidone; Described disintegrating agent is self-crosslinking sodium carboxymethyl cellulose most preferably; Described sweeting agent is selected from the one in aspartame, sucralose, and described aromatic is selected from the one in blueberry flavor, Fructus Citri Limoniae essence; Described sweeting agent is most preferably from sucralose, and described aromatic is most preferably from blueberry flavor; In described dispersible tablet Utimox and clavulanate potassium respectively in the weight ratio of amoxicillin and clavulanic acid for 4:1; Described dispersible tablet adopts direct powder compression to be prepared; Described dispersible tablet is made up of the component of following weight percents: Utimox 21.66%, clavulanate potassium 5.62%, microcrystalline Cellulose 66.03%, cross-linking sodium carboxymethyl cellulose 2.51%, kieselguhr 3.77%, blueberry flavor 0.25%, sucralose 0.16%.
Main points of the present invention are a kind of amoxicillin and clavulanate potassium dispersible tablet.Its principle is: (1), when adopting cross-linking sodium carboxymethyl cellulose to be disintegrating agent, can shorten the disintegration of dispersible tablet greatly, especially under the low temperature of 5 DEG C, still can be shortened disintegration fast by adding kieselguhr in prescription.(2) by adding kieselguhr in prescription, not adding other antiplastering aid or lubricant, when as micropowder silica gel or magnesium stearate, still can make the good fluidity of prescription mixed powder, not sticking.(3) by using the combination of blueberry flavor and sucralose to carry out taste masking in prescription, the good mouthfeel after dispersible tablet can be made to dissolve, without bilgy odour.(4) by adding kieselguhr in prescription, the stability of dispersible tablet can be made better.
A kind of amoxicillin and clavulanate potassium dispersible tablet compared with prior art, have disintegrate fast, still can fater disintegration under lower water temperature, good stability, mouthfeel is good, prescription is simple, prescription mixed powder good fluidity, tableting processes be the advantage such as sticking not, will be widely used in the formulation art of amoxicillin and clavulanate potassium dispersible tablet.
Below in conjunction with embodiment, the present invention is described in detail.
Detailed description of the invention
Following examples for illustration of the present invention, but are not used for limiting the scope of the invention.
Embodiment one
When table 1 adopts cross-linking sodium carboxymethyl cellulose to be disintegrating agent, the prescription of the different addition of kieselguhr
Employing direct powder compression is prepared, and concrete grammar is as follows:
Various active component and adjuvant is taken by prescription, cross 100 mesh sieves respectively, wherein microcrystalline Cellulose 60 DEG C of dryings 2 hours, various adjuvant adds in the mixed powder of Utimox and clavulanate potassium according to equal increments method, in mixer after mix homogeneously, discharging, carries out tabletting with the special-shaped punch die of ellipse, obtains amoxicillin and clavulanate potassium (4:1) dispersible tablet.
Embodiment two
When table 2 adopts carboxymethyl starch sodium to be disintegrating agent, the prescription of the different addition of kieselguhr
Employing direct powder compression is prepared, and concrete grammar is as follows:
Various active component and adjuvant is taken by prescription, cross 100 mesh sieves respectively, wherein microcrystalline Cellulose 60 DEG C of dryings 2 hours, various adjuvant adds in the mixed powder of Utimox and clavulanate potassium according to equal increments method, in mixer after mix homogeneously, discharging, carries out tabletting with the special-shaped punch die of ellipse, obtains amoxicillin and clavulanate potassium (4:1) dispersible tablet.
Embodiment three
When table 3 adopts polyvinylpolypyrrolidone to be disintegrating agent, the prescription of the different addition of kieselguhr
Employing direct powder compression is prepared, and concrete grammar is as follows:
Various active component and adjuvant is taken by prescription, cross 100 mesh sieves respectively, wherein microcrystalline Cellulose 60 DEG C of dryings 2 hours, various adjuvant adds in the mixed powder of Utimox and clavulanate potassium according to equal increments method, in mixer after mix homogeneously, discharging, carries out tabletting with the special-shaped punch die of ellipse, obtains amoxicillin and clavulanate potassium (4:1) dispersible tablet.
Embodiment four
When table 4 adopts cross-linking sodium carboxymethyl cellulose to be disintegrating agent, the prescription of the different addition of adjuvant
Employing direct powder compression is prepared, and concrete grammar is as follows:
Various active component and adjuvant is taken by prescription, cross 100 mesh sieves respectively, wherein microcrystalline Cellulose 60 DEG C of dryings 2 hours, various adjuvant adds in the mixed powder of Utimox and clavulanate potassium according to equal increments method, in mixer after mix homogeneously, discharging, carries out tabletting with the special-shaped punch die of ellipse, obtains amoxicillin and clavulanate potassium (4:1) dispersible tablet.
Embodiment five
When table 5 adopts cross-linking sodium carboxymethyl cellulose to be disintegrating agent, the prescription of different correctivess
Employing direct powder compression is prepared, and concrete grammar is as follows:
Various active component and adjuvant is taken by prescription, cross 100 mesh sieves respectively, wherein microcrystalline Cellulose 60 DEG C of dryings 2 hours, various adjuvant adds in the mixed powder of Utimox and clavulanate potassium according to equal increments method, in mixer after mix homogeneously, discharging, carries out tabletting with the special-shaped punch die of ellipse, obtains amoxicillin and clavulanate potassium (4:1) dispersible tablet.
Embodiment six
Table 6 adopts the prescription of different lubricant
Employing direct powder compression is prepared, and concrete grammar is as follows:
Various active component and adjuvant is taken by prescription, cross 100 mesh sieves respectively, wherein microcrystalline Cellulose 60 DEG C of dryings 2 hours, various adjuvant adds in the mixed powder of Utimox and clavulanate potassium according to equal increments method, in mixer after mix homogeneously, discharging, carries out tabletting with the special-shaped punch die of ellipse, obtains amoxicillin and clavulanate potassium (4:1) dispersible tablet.
Testing result for above prescription is as follows:
1, dispersing uniformity
Carry out according to the method for " dispersing uniformity " item in Chinese Pharmacopoeia 2010 editions second annex IA.
Get test sample 6, put in 250ml beaker, add the water 100ml of 15-25 DEG C, jolting 3 minutes, all disintegrate also should pass through No. two sieves.In this test, specifically have selected 15 DEG C, 25 DEG C and lower temperature 5 DEG C is tested.
When table 7 adopts cross-linking sodium carboxymethyl cellulose to be disintegrating agent, diatomaceous different addition is on the impact of prescription disintegration
Illustrate: the LVFS in table refer to prescription at the same temperature with contrast prescription compared with disintegration shorten percentage rate.
Can find out, prescription 1 to prescription 5 compares with contrast prescription 1, and its disintegration all significantly shortens than the disintegration of the contrast prescription 1 under same temperature, and wherein prescription 3 LVFS is at each temperature the highest.
When table 8 adopts carboxymethyl starch sodium to be disintegrating agent, diatomaceous different addition is on the impact of prescription disintegration
Illustrate: the LVFS in table refer to prescription at the same temperature with contrast prescription compared with disintegration shorten percentage rate.
Can find out, prescription 6 to prescription 10 compares with contrast prescription 2, and its disintegration slightly shortened than the disintegration of the contrast prescription 2 under same temperature, and wherein prescription 9 LVFS is at each temperature the highest.
When table 9 adopts polyvinylpolypyrrolidone to be disintegrating agent, diatomaceous different addition is on the impact of prescription disintegration
Illustrate: the LVFS in table refer to prescription at the same temperature with contrast prescription compared with disintegration shorten percentage rate.
Can find out, prescription 11 to prescription 15 compares with contrast prescription 3, and its disintegration slightly shortened than the disintegration of the contrast prescription 3 under same temperature, and wherein prescription 12 LVFS is at each temperature the highest.
When table 10 adopts cross-linking sodium carboxymethyl cellulose to be disintegrating agent, different ratio of adjuvant is on the impact of prescription disintegration
Illustrate: the LVFS in table refer to prescription at the same temperature with contrast prescription compared with disintegration shorten percentage rate.
Can find out, prescription 16 to prescription 19 compares with contrast prescription 1, and its disintegration significantly shortened than the disintegration of the contrast prescription 1 under same temperature.
When table 11 adopts cross-linking sodium carboxymethyl cellulose to be disintegrating agent, different correctivess is on the impact of prescription disintegration
Illustrate: the LVFS in table refer to prescription at the same temperature with contrast prescription compared with disintegration shorten percentage rate.
Can find out, prescription 20 to prescription 22 compares with contrast prescription 1, and its disintegration significantly shortened than the disintegration of the contrast prescription 1 under same temperature.
When table 12 adopts cross-linking sodium carboxymethyl cellulose to be disintegrating agent and do not add kieselguhr, different lubricants is on the impact of prescription disintegration
Illustrate: the LVFS in table refer to prescription at the same temperature with contrast prescription compared with disintegration shorten percentage rate.
Can find out, contrast prescription 4 compares with contrast prescription 1, its disintegration is than slightly extending the disintegration of the contrast prescription 1 under same temperature or maintaining an equal level, contrast prescription 5, contrast prescription 6 compare with contrast prescription 1, and its disintegration slightly shortened than the disintegration of the contrast prescription 1 under same temperature.
2, mobility and sticking
Mobility embodied with angle of repose, and the assay method of angle of repose is as follows:
Adopt the comprehensive analyzer of powder to combine fixing conical bottom method to measure: get a certain amount of powder to be measured, under certain frequency of vibration (about 100nz), powder is evenly flowed out by funnel, until obtain the highest cone, measure the angle of cone inclined-plane and plane and get final product, each measurement repetition 3 times, gets its meansigma methods.Mixed powder after prescription active component each in embodiment and adjuvant mix homogeneously is carried out to the test of angle of repose and sticking, the results are shown in Table 13.
The mobility of each prescription of table 13 and sticking
| Prescription sequence number | Mobility (angle of repose) | Sticking | Prescription sequence number | Mobility (angle of repose) | Sticking |
| Prescription 1 | 36° | No | Prescription 13 | 34° | No |
| Prescription 2 | 36° | No | Prescription 14 | 34° | No |
| Prescription 3 | 35° | No | Prescription 15 | 33° | No |
| Prescription 4 | 35° | No | Contrast prescription 3 | 45° | Be |
| Prescription 5 | 34° | No | Prescription 16 | 36° | No |
| Contrast prescription 1 | 46° | Be | Prescription 17 | 35° | No |
| Prescription 6 | 38° | No | Prescription 18 | 35° | No |
| Prescription 7 | 38° | No | Prescription 19 | 34° | No |
| Prescription 8 | 37° | No | Prescription 20 | 35° | No |
| Prescription 9 | 36° | No | Prescription 21 | 35° | No |
| Prescription 10 | 36° | No | Prescription 22 | 35° | No |
| Contrast prescription 2 | 50° | Be | Contrast prescription 4 | 37° | No |
| Prescription 11 | 35° | No | Contrast prescription 5 | 32° | No |
| Prescription 12 | 35° | No | Contrast prescription 6 | 35° | Slight sticking |
3, mouthfeel
Method of testing: 20 volunteers, men and women half and half, between age 25-30 year.Get the dispersible tablet of 1 prescription to be tested, every sheet is containing amoxicillin (in anhydride) 125mg, clavulanate potassium (in clavulanic acid) 31.25mg, insert in the water tumbler filling 150ml water, water temperature is about 20 DEG C, after dispersible tablet disperses completely, rock water tumbler, taste after making Dispersion of Solute Matter evenly, the test result of each prescription is in table 14:
The sensory test of table 14 prescription
| Prescription sequence number | Bad | Generally | Good | Feature |
| Prescription 3 | 0 | 4 | 16 | Micro-perfume (or spice) is micro-sweet in bilgy odour |
| Prescription 20 | 0 | 8 | 12 | Slightly bilgy odour |
| Prescription 21 | 2 | 8 | 10 | Slightly bilgy odour |
| Prescription 22 | 0 | 8 | 12 | Slightly bilgy odour |
4, the detection of content, dissolution, related substance, moisture
Carry out accelerated test according to the method for Chinese Pharmacopoeia 2010 editions two text kind Part I " amoxicillin and clavulanate potassium dispersible tablet ", the dispersible tablet of each prescription adopts two In Aluminium Foil Packing, the results are shown in Table 15,16.
The accelerated test (character, content, moisture and related substance) of table 15 prescription
The accelerated test (dissolution) of table 16 prescription
Illustrate: the kieselguhr adopted in prescription of the present invention is white diatomite, granularity is 200-300 order; It is the microcrystalline Cellulose of PH102 that the microcrystalline Cellulose adopted in prescription of the present invention is the auspicious model of stepping on the production of Mel father and son company of Germany.
Claims (2)
1. an amoxicillin and clavulanate potassium dispersible tablet, it is characterized in that: described dispersible tablet is made up of the component of following weight percents: Utimox 21.66%, clavulanate potassium 5.62%, microcrystalline Cellulose 66.03%, cross-linking sodium carboxymethyl cellulose 2.51%, kieselguhr 3.77%, blueberry flavor 0.25%, sucralose 0.16%.
2. a kind of amoxicillin and clavulanate potassium dispersible tablet according to claim 1, is characterized in that: described dispersible tablet adopts direct powder compression to be prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410028419.8A CN103768056B (en) | 2014-01-21 | 2014-01-21 | Amoxicillin and clavulanate potassium dispersible tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410028419.8A CN103768056B (en) | 2014-01-21 | 2014-01-21 | Amoxicillin and clavulanate potassium dispersible tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103768056A CN103768056A (en) | 2014-05-07 |
| CN103768056B true CN103768056B (en) | 2015-01-07 |
Family
ID=50561120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410028419.8A Active CN103768056B (en) | 2014-01-21 | 2014-01-21 | Amoxicillin and clavulanate potassium dispersible tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103768056B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161734B (en) * | 2014-09-04 | 2017-03-29 | 海口市制药厂有限公司 | A kind of amoxicillin dispersible tablet, Preparation Method And The Use |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1803135A (en) * | 2006-01-24 | 2006-07-19 | 沈阳施德药业有限公司 | Amoxicillin-potsssium clavulanate dispersion tablet |
| WO2007058397A1 (en) * | 2005-11-17 | 2007-05-24 | Gl Pharmtech Corp. | A dispersible tablet comprising the mixture of amoxicillin and clavulanic acid or its salts and processes for preparing the same |
| CN101190217A (en) * | 2006-11-22 | 2008-06-04 | 上海新亚药业闵行有限公司 | Amoxicillin clavulanate potassium 4:1 dispersible tablet and production technology thereof |
| CN101332196A (en) * | 2007-06-28 | 2008-12-31 | 上海华氏制药有限公司 | Amoxicillin/clavulanate potassium dispersible tablets and preparation method thereof |
| CN102600141A (en) * | 2012-02-24 | 2012-07-25 | 南京臣功制药股份有限公司 | Dispersible tablet containing amoxicillin and potassium clavulanate |
-
2014
- 2014-01-21 CN CN201410028419.8A patent/CN103768056B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007058397A1 (en) * | 2005-11-17 | 2007-05-24 | Gl Pharmtech Corp. | A dispersible tablet comprising the mixture of amoxicillin and clavulanic acid or its salts and processes for preparing the same |
| CN1803135A (en) * | 2006-01-24 | 2006-07-19 | 沈阳施德药业有限公司 | Amoxicillin-potsssium clavulanate dispersion tablet |
| CN101190217A (en) * | 2006-11-22 | 2008-06-04 | 上海新亚药业闵行有限公司 | Amoxicillin clavulanate potassium 4:1 dispersible tablet and production technology thereof |
| CN101332196A (en) * | 2007-06-28 | 2008-12-31 | 上海华氏制药有限公司 | Amoxicillin/clavulanate potassium dispersible tablets and preparation method thereof |
| CN102600141A (en) * | 2012-02-24 | 2012-07-25 | 南京臣功制药股份有限公司 | Dispersible tablet containing amoxicillin and potassium clavulanate |
Non-Patent Citations (2)
| Title |
|---|
| 阿莫西林克拉维酸钾分散片制备工艺与溶出度考察;黄国军等;《医药导报》;20061101;第25卷(第11期);1185 * |
| 阿莫西林克拉维酸钾分散片的制备工艺研究;欧阳亦华等;《今日药学》;20131025;第23卷(第10期);664 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103768056A (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kadivar et al. | Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet | |
| CN101489530A (en) | Oral controlled release formulations of an interleukin-1 beta converting enzyme inihibitor | |
| CN105640900A (en) | Perampanel medicinal composition | |
| CN103768056B (en) | Amoxicillin and clavulanate potassium dispersible tablet | |
| CN104055743A (en) | Preparation method of oral preparation containing rivaroxaban | |
| CN105434376A (en) | Meisuoshuli orally disintegrating tablet and preparation method thereof | |
| CN104510719A (en) | Acotiamide tablet and preparation method thereof | |
| CN109248150B (en) | Amoxicillin and clavulanate potassium preparation and preparation method thereof | |
| CN103919741A (en) | Penicillin V potassium tablet and preparation method thereof | |
| CN103127011A (en) | Roflumilast tablet and preparation method thereof | |
| CN106974891A (en) | Treat the preparation method of the Olanzapine oral disnitegration tablet of depression | |
| Mariana | Greco-Latin square design for selection of excipients in the development of metformin orodispersible tablets | |
| CN100353943C (en) | Fleroxacin lactate dispersion tablet, and its prepn. method | |
| CN103816135A (en) | Memantine hydrochloride sustained release preparation and preparing method thereof | |
| CN104983711A (en) | Vilazodone hydrochloride capsule composition | |
| CN105769883A (en) | Compound sulfamethoxazole dispersible tablet and preparation method thereof | |
| CN103301081A (en) | Cefdinir dispersible tablet and preparation method thereof | |
| CN104116718A (en) | Itopride hydrochloride oral preparation | |
| CN103494821B (en) | A kind of cefixime composition | |
| CN102861015B (en) | Stable amoxicillin and clavulanate potassium sustained release preparation and preparation technology | |
| CN113768889B (en) | Cilostazol-containing pharmaceutical composition and preparation method thereof | |
| CN103142544B (en) | Ubenimex capsule composition and preparation method thereof | |
| CN103417535B (en) | A kind of amoxicillin and clavulanate potassium tablets and preparation method thereof | |
| EP2976067B1 (en) | Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof | |
| CN105769799A (en) | Moxixacin tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |